A phase II study of recombinant tumor necrosis factor in renal cell carcinoma : a study of the national cancer institute of Canada clinical trials group

The National Cancer Institute (NCI) Canada Clinical Trials Group conducted a phase II study of recombinant tumor necrosis factor (rTNF) given intravenously daily for 5 days every other week, in measurable metastatic renal cell carcinoma. Two of 26 patients responded with responses lasting greater th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of immunotherapy 1992, Vol.11 (1), p.67-70
Hauptverfasser:	SKILLINGS, J, WIERZBICKI, R, EISENHAUER, E, VENNER, P, LETENDRE, F, STEWART, D, WEINERMAN, B
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic agents Biological and medical sciences Carcinoma - diagnostic imaging Carcinoma - pathology Carcinoma - therapy Drug Evaluation Female Humans Immunotherapy Kidney Neoplasms - diagnostic imaging Kidney Neoplasms - pathology Kidney Neoplasms - therapy Male Medical sciences Middle Aged Pharmacology. Drug treatments Recombinant Proteins - therapeutic use Tomography, X-Ray Computed Tumor Necrosis Factor-alpha - adverse effects Tumor Necrosis Factor-alpha - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The National Cancer Institute (NCI) Canada Clinical Trials Group conducted a phase II study of recombinant tumor necrosis factor (rTNF) given intravenously daily for 5 days every other week, in measurable metastatic renal cell carcinoma. Two of 26 patients responded with responses lasting greater than 200 days. Toxicity was severe including rigors, fever, headache, fatigue, hypotension, and localized pain. We conclude that rTNF, given as described, has only modest antitumor activity in renal cell carcinoma and produces considerable toxicity. We plan no further studies of rTNF in this disease.
ISSN:	1053-8550 1524-9557 2331-3668
DOI:	10.1097/00002371-199201000-00008